Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) will hold a live webcast and conference call on March 3, 2022, at 8:30 a.m. ET to discuss its Q4 and FY 2021 financial results and provide a business update. The webcast can be accessed via the Investor Relations section of the Wave Life Sciences website. The company's proprietary PRISM platform focuses on developing genetic medicines, targeting genetically defined diseases. Investors can dial in for the call using provided numbers and enter the conference ID: 7694386. An archived version will be available post-event.

Positive

• Management will provide a business update, indicating strategic focus.
• The company utilizes a proprietary platform, PRISM, enhancing drug development potential.

Negative

• None.

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, March 3, 2022, to discuss its fourth quarter and full year 2021 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting the “Events” section on the Investor Relations page of the Wave Life Sciences website at www.wavelifesciences.com. The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 7694386. Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com 

FAQ

What is the date of Wave Life Sciences' Q4 2021 earnings call?

Wave Life Sciences will host its Q4 2021 earnings call on March 3, 2022.

How can I access the Wave Life Sciences conference call?

The conference call can be accessed via the Investor Relations page of Wave Life Sciences' website or by dialing (866) 220-8068 for domestic calls or (470) 495-9153 for international calls.

What is the main focus of Wave Life Sciences?

Wave Life Sciences focuses on developing genetic medicines for devastating diseases using its PRISM platform.

What information will Wave Life Sciences provide in its earnings call?

Wave Life Sciences will discuss its fourth quarter and full year 2021 financial results and offer a business update during the call.